205 related articles for article (PubMed ID: 32023088)
1. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
Nagaria TS; Wang H; Chatterjee D; Wang H
Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
[TBL] [Abstract][Full Text] [Related]
2. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
[TBL] [Abstract][Full Text] [Related]
4. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.
Wang H; Chetty R; Hosseini M; Allende DS; Esposito I; Matsuda Y; Deshpande V; Shi J; Dhall D; Jang KT; Kim GE; Luchini C; Graham RP; Reid MD; Basturk O; Hruban RH; Krasinskas A; Klimstra DS; Adsay V;
Am J Surg Pathol; 2022 Jun; 46(6):754-764. PubMed ID: 34889852
[TBL] [Abstract][Full Text] [Related]
5. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
6. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
7. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
8. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
Chatterjee D; Katz MH; Foo WC; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
Am J Surg Pathol; 2017 Aug; 41(8):1097-1104. PubMed ID: 28614206
[TBL] [Abstract][Full Text] [Related]
10. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
[TBL] [Abstract][Full Text] [Related]
11. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma.
Rowan DJ; Hartley CP; Aldakkak M; Christians KK; Evans DB; Tsai S; Hagen CE
Ann Diagn Pathol; 2020 Jun; 46():151485. PubMed ID: 32172219
[TBL] [Abstract][Full Text] [Related]
12. Residual Tumor Index: A Prognostically Significant Pathologic Parameter in Neoadjuvant-treated Pancreatic Ductal Adenocarcinoma.
Panni RZ; Gonzalez I; Hartley CP; Williams GA; Liu J; Hawkins WG; Chatterjee D
Am J Surg Pathol; 2018 Nov; 42(11):1480-1487. PubMed ID: 30179901
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
Brown ZJ; Shannon AH; Cloyd JM
Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
[TBL] [Abstract][Full Text] [Related]
14. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
15. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer.
Perri G; Prakash L; Wang H; Bhosale P; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay E; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
Ann Surg; 2021 Apr; 273(4):806-813. PubMed ID: 31274655
[TBL] [Abstract][Full Text] [Related]
16. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
17. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC.
Oba A; Bao QR; Barnett CC; Al-Musawi MH; Croce C; Schulick RD; Del Chiaro M
Scand J Surg; 2020 Mar; 109(1):18-28. PubMed ID: 31960765
[TBL] [Abstract][Full Text] [Related]
18. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
[TBL] [Abstract][Full Text] [Related]
19. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
20. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome.
Das R; McGrath K; Seiser N; Smith K; Uttam S; Brand RE; Fasanella KE; Khalid A; Chennat JS; Sarkaria S; Singh H; Slivka A; Zeh HJ; Zureikat AH; Hogg ME; Lee KK; Paniccia A; Ongchin MC; Pingpank JF; Boone BA; Dasyam AK; Bahary N; Gorantla VC; Rhee JC; Thomas R; Ellsworth S; Landau MS; Ohori NP; Henn P; Shyu S; Theisen BK; Singhi AD
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):886-897. PubMed ID: 33278573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
